Cargando…
A randomized pilot efficacy and safety trial of diazoxide choline controlled-release in patients with Prader-Willi syndrome
INTRODUCTION: Prader-Willi syndrome (PWS) is a complex genetic condition characterized by hyperphagia, hypotonia, low muscle mass, excess body fat, developmental delays, intellectual disability, behavioral problems, and growth hormone deficiency. This study evaluated the safety and efficacy of orall...
Autores principales: | Kimonis, Virginia, Surampalli, Abhilasha, Wencel, Marie, Gold, June-Anne, Cowen, Neil M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756513/ https://www.ncbi.nlm.nih.gov/pubmed/31545799 http://dx.doi.org/10.1371/journal.pone.0221615 |
Ejemplares similares
-
Diazoxide Choline Extended-Release Tablet in People With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled Trial
por: Miller, Jennifer L, et al.
Publicado: (2023) -
Early Diagnosis in Prader–Willi Syndrome Reduces Obesity and Associated Co-Morbidities
por: Kimonis, Virginia E., et al.
Publicado: (2019) -
OR10-2 Hormonal and Cardiometabolic Changes Associated with Diazoxide Choline Extended-Release (DCCR) Tablets in Patients with Prader-Willi Syndrome
por: Abuzzahab, Jennifer, et al.
Publicado: (2022) -
RF24 | PSUN94 Long-Term Safety of Diazoxide Choline Extended-Release (DCCR) Tablets in Patients with Prader-Willi Syndrome
por: Woloschak, Michael, et al.
Publicado: (2022) -
Clinical Trials in Prader–Willi Syndrome: A Review
por: Mahmoud, Ranim, et al.
Publicado: (2023)